U.S. Prostate Cancer Testing Market - A Country Analysis

2.1    Overview
2.2    Legal Requirements and Framework in the U.S
         2.2.1    National Comprehensive Cancer Network (NCCN) Guidelines
         2.2.2    American Urological Association (AUA)
         2.2.3    American Cancer Society (ACS)
         2.2.4    U.S. Preventive Services Task Force (USPSTF)
2.3    Patent Analysis
         2.3.1    Patent Filing Trend
2.4    Role of Biomarkers in Prostate Cancer Management

3.1    Overview
         3.1.1    Impact Analysis
3.2    Market Drivers
3.3    Market Restraints
3.4    Market Opportunities

4.1    Overview
4.2    Corporate Strategies
         4.2.1    Mergers and Acquisitions
         4.2.2    Synergistic Activities
         4.2.3    Business Expansions and Funding
4.3    Business Strategies
         4.3.1    Product Launches and Approvals
         4.3.2    Publications
         4.3.3    Licenses and Agreements
         4.3.4    Other Activities
4.4    Reimbursement Scenario in the U.S.

5.1    Overview
5.2    Initial Evaluation: Prostate-Specific Antigen (Total PSA, Free PSA)
5.3    Pre-Biopsy/Post-Negative Biopsy Testing
         5.3.1    Blood-Based Biomarker
         5.3.2    Urine-Based Biomarker
         5.3.3    Imaging
                     5.3.3.1    Multiparametric Magnetic Resonance Imaging (mp-MRI)
5.4    Post-Biopsy Tissue Testing
5.5    Post-Biopsy Test

6.1    Overview
6.2    Prostatic Adenocarcinoma
6.3    Small Cell Carcinoma
6.4    Other Prostate Cancer Type

7.1    Overview
7.2    Clinical Diagnostic Biomarkers
7.3    Prognostic Biomarkers (Prolaris, OncotypeDx, Decipher, etc.)

8.1    Overview
8.2    Cancer Research Institutes
8.3    Diagnostic Laboratories
8.4    Hospitals and Clinics
8.5    Ambulatory Surgical Centers (ASCs)
8.6    Others

9.1    Overview
9.2    Northeast U.S.
         9.2.1    Northeast U.S. (Prostate-Specific Antigen (PSA)
         9.2.2    Northeast U.S. (Pre-Biopsy/Post-Negative Biopsy Testing)
         9.2.3    Northeast U.S. (Post-Biopsy Tissue Testing)
9.3    Midwest U.S.
         9.3.1    Midwest U.S. (Prostate-Specific Antigen (PSA)
         9.3.2    Midwest U.S. (Pre-Biopsy/Post-Negative Biopsy Testing)
         9.3.3    Midwest U.S. (Post-Biopsy Tissue Testing)
9.4    South U.S.
         9.4.1    South U.S. (Prostate-Specific Antigen (PSA)
         9.4.2    South  U.S. (Pre-Biopsy/Post-Negative Biopsy Testing)
         9.4.3    South U.S. (Post-Biopsy Tissue Testing)
9.5    West U.S.
         9.5.1    West U.S. (Prostate-Specific Antigen (PSA)
         9.5.2    West U.S. (Pre-Biopsy/Post-Negative Biopsy Testing)
         9.5.3    West U.S. (Post-Biopsy Tissue Testing)

10.1    Abbott
           10.1.1    Overview
           10.1.2    Top Products / Product Portfolio
           10.1.3    Top Competitors
           10.1.4    Target Customers/End-Users
           10.1.5    Key Personnel
           10.1.6    Analyst View
10.2    Abcam plc.
           10.2.1    Overview
           10.2.2    Top Products / Product Portfolio
           10.2.3    Top Competitors
           10.2.4    Target Customers/End-Users
           10.2.5    Key Personnel
           10.2.6    Analyst View
10.3    Agilent Technologies, Inc.
           10.3.1    Overview
           10.3.2    Top Products / Product Portfolio
           10.3.3    Top Competitors
           10.3.4    Target Customers/End-Users
           10.3.5    Key Personnel
           10.3.6    Analyst View
10.4    Bio-Techne. (ExoDx)
           10.4.1    Overview
           10.4.2    Top Products / Product Portfolio
           10.4.3    Top Competitors
           10.4.4    Target Customers/End-Users
           10.4.5    Key Personnel
           10.4.6    Analyst View
10.5    Cleveland Diagnostics, Inc.
           10.5.1    Overview
           10.5.2    Top Products / Product Portfolio
           10.5.3    Top Competitors
           10.5.4    Target Customers/End-Users
           10.5.5    Key Personnel
           10.5.6    Analyst View
10.6    Danaher. (Beckman Coulter, Inc.)
           10.6.1    Overview
           10.6.2    Top Products / Product Portfolio
           10.6.3    Top Competitors
           10.6.4    Target Customers/End-Users
           10.6.5    Key Personnel
           10.6.6    Analyst View
10.7    Exact Sciences Corporation
           10.7.1    Overview
           10.7.2    Top Products / Product Portfolio
           10.7.3    Top Competitors
           10.7.4    Target Customers/End-Users
           10.7.5    Key Personnel
           10.7.6    Analyst View
10.8    F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.)
           10.8.1    Overview
           10.8.2    Top Products / Product Portfolio
           10.8.3    Top Competitors
           10.8.4    Target Customers/End-Users
           10.8.5    Key Personnel
           10.8.6    Analyst View
10.9    H.U. Group Holdings, Inc. (Fujeribio)
           10.9.1    Overview
           10.9.2    Top Products / Product Portfolio
           10.9.3    Top Competitors
           10.9.4    Target Customers/End-Users
           10.9.5    Key Personnel
           10.9.6    Analyst View
10.10    Mdxhealth
           10.10.1    Overview
           10.10.2    Top Products / Product Portfolio
           10.10.3    Top Competitors
           10.10.4    Target Customers/End-Users
           10.10.5    Key Personnel
           10.10.6    Analyst View
10.11    Siemens Healthcare GmbH
             10.11.1    Overview
             10.11.2    Top Products / Product Portfolio
             10.11.3    Top Competitors
             10.11.4    Target Customers/End-Users
             10.11.5    Key Personnel
             10.11.6    Analyst View
10.12    Myriad Genetics, Inc.
             10.12.1    Overview
             10.12.2    Top Products / Product Portfolio
             10.12.3    Top Competitors
             10.12.4    Target Customers/End-Users
             10.12.5    Key Personnel
             10.12.6    Analyst View
10.13    NeoGenomics Laboratories
             10.13.1    Overview
             10.13.2    Top Products / Product Portfolio
             10.13.3    Top Competitors
             10.13.4    Target Customers/End-Users
             10.13.5    Key Personnel
             10.13.6    Analyst View
10.14    OPKO Health, Inc. (GenPath)
             10.14.1    Overview
             10.14.2    Top Products / Product Portfolio
             10.14.3    Top Competitors
             10.14.4    Target Customers/End-Users
             10.14.5    Key Personnel
             10.14.6    Analyst View
10.15    Veracyte, Inc.
             10.15.1    Overview
             10.15.2    Top Products / Product Portfolio
             10.15.3    Top Competitors
             10.15.4    Target Customers/End-Users
             10.15.5    Key Personnel
             10.15.6    Analyst View

Table:    U.S. Prostate Cancer Testing Market, Patent Analysis, January 2022-March 2025 
Table:    U.S.Prostate Cancer Testing Market Dynamics, Impact Analysis
Table:    U.S.Prostate Cancer Testing Market (by Biomarker Type), $Million, 2023-2035
Table:    U.S.Prostate Cancer Testing Market (by Cancer Type), $Million, 2023-2035
Table:    U.S.Prostate Cancer Testing Market (by Application), $Million, 2023-2035
Table:    U.S. Prostate Cancer Testing Market (by End User), $Million, 2023-2035
Table:    U.S. Prostate Cancer Testing Market (by Region), $Million, 2023-2035

Figure:    U.S. Prostate Cancer Testing Market, Dynamics Impact Analysis
Figure:    U.S.Prostate Cancer Testing Market Coverage
Figure:    U.S.Prostate Cancer Testing Market Key Trends, Impact Analysis, 2023-2035
Figure:    U.S.Prostate Cancer Testing Market, Patent Analysis, January 2022-March 2025